Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors

Neuropsychopharmacology

Volumn 23, Issue 5, 2000, Pages 569-576

  Gewirtz, Jonathan C ^a   Marek, Gerard J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 HT(2A) receptors; DOI; Hallucinogens; Head shakes; LY354740; mGlu2 3 receptors; Phenethylamines; Serotonin

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINOBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; GLUTAMIC ACID; METABOTROPIC RECEPTOR; PSYCHEDELIC AGENT; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN 2A RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR; DRUG RECEPTOR BINDING; ELECTROPHYSIOLOGY; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RAT;

AMINO ACIDS; AMPHETAMINES; ANIMAL; BEHAVIOR, ANIMAL; BICYCLO COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; HALLUCINOGENS; MALE; PYRAMIDAL CELLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; RECEPTORS, SEROTONIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; XANTHENES;

EID: 0033797463     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(00)00136-6     Document Type: Article

References (74)

1. Adler L.E., Olincy A., Waldo M., Harris J.G., Griffith J., Stevens K., Flach K., Nagamoto H., Bickford P., Leonard S., Freedman R. Schizophrenia, sensory gating, and nicotinic receptors. Schizophrenia Bull. 24:1998;189-202.
2. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
3. Aghajanian G.K., Marek G.J. Serotonin-glutamate interactions. a new target for antipsychotic drugs Neuropsychopharmacol. 21:1999;S122-S133.
4. Altar C.A., Wasley A.M., Neale R.F., Stone G.A. Typical and atypical antipsychotic occupancy of D2 and S2 receptors. An autoradiographic analysis in rat brain Brain Res Bull. 16:1986;517-525.
5. 2A agonist DOI. Soc Neurosci Abstr. 24:1998;1369.
6. 1) partial agonist in the treatment of major depression. Prog Neuro-Psychopharmacol & Biol-Psychiat. 16:1992;271-280.
7. Arnt J., Hyttel J. Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. European Journal of Pharmacology. 161:1989;45-51.
8. Battaglia G., Monn J.A., Schoepp D.D. In vivo inhibition of veratridine-induced release of excitatory amino acids by the group II metabotropic agonist LY354740 in rats. Neurosci Lett. 229:1997;161-164.
9. Bedard P., Pycock C.J. 'Wet-dog' shake behaviour in the rat. a possible quantitative model of central 5-hydroxytryptamine activity Neuropharmacology. 16:1977;663-670.
10. Berendse H.W., Groenewegen H.J. Restricted cortical termination fields of the midline and intralaminar thalamic nuclei in the rat. Neuroscience. 42:1991;73-102.
11. 2 receptors and serotonergic axons in rat neocortex. Brain Res. 453:1988;315-328.
12. Bodkin J.A., Zornberg G.L., Lukas S.E., Cole J.O. Buprenorphine treatment of refractory depression. Journal of Clinical Psychopharmacology. 15:1995;49-57.
13. 2 receptors. Life Sciences. 42:1988;2439-2445.
14. Carlson E.T., Simpson M.M. Opium as a tranquilizer. American Journal of Psychiatry. 120:1963;112-117.
15. Cartmell J., Monn J.A., Schoepp D.D. The mGlu2/3 receptor agonists, LY354740 and LY379268, selectively attenuate phencyclidine versus d-amphetamine motor behavior in rats. J Pharmacol Exp Ther. 291:1999;161-170.
16. Ceulemans D.L.S., Gelders Y.G., Hoppenbrouwers M.-L.J.A., Reyntjens A.J.M., Janssen P.A.J. Effect of serotonin antagonism in schizophrenia. A pilot study with setoperone Psychopharmacol. 85:1985;329-332.
17. Colpaert F.C., Janssen P.A.J. The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat. antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist Neuropharmacol. 22:1983;993-1000.
18. Colpaert F.C., Niemegeers C.J.E., Janssen P.A.J. A drug discrimination analysis of lysergic acid diethylamide (LSD). In vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, a LSD-antagonist J Pharmacol Exp Ther. 221:1982;206-214.
19. Comfort A. Morphine as an antipsychotic? Clinical Toxicology. 11:1977;383-386.
20. Conn P.J., Pin J.-P. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 37:1997;205-237.
21. Corne S.J., Pickering R.W., Warner B.T. A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine. Br J Pharmacol. 20:1963;106-120.
22. Covey L.S., Glassman A.H., Stetner F. Major depression following smoking cessation. Am J Psychiatry. 154:1997;263-265.
23. 2 receptors? Pharmacol. Behav Biochem. 36:1990;901-906.
24. de Boer T. The pharmacologic profile of mirtazepine. Journal of Clinical Psychiatry. 57:1996;19-25.
25. Eison A.S., Eison M.S., Torrente J.R., Wright R.N., Yocca F.D. Nefazodone. preclinical pharmacology of a new antidepressant Psychopharmacology Bulletin. 26:1990;311-315.
26. 2A receptor are insensitive to many of the behavioral and physiological effects of hallucinogens. Soc Neurosci Abstr. 25:1999;799.
27. 2 agonists or antagonists? Neuropsychopharmacol. 3:1990;509-517.
28. Gold M.S., Donabedian R.K., Dillard M., Slobetz F.W., Riordan C.E., Kleber H.D. Antipsychotic effect of opiate agonists. The Lancet. 2:1977;398-399.
29. Granhoff M.I., Lee L., Jackson A., Patel K., Martinez Y., Ashby C.R., Wang R.Y. The interaction of 5-HT1A and 5-HT2 receptors in the medial prefrontal cortex. Behavioral studies Society for Neurosciences (Abstract). 18:1992;1380. a.
30. 2 receptors in the medial prefrontal cortex. Behavioral studies Soc Neurosci (Abstr). 18:1992;1380. b.
31. 1A receptors. Neuropharmacol. 25:1986;1307-1313.
32. 1A receptors. J Neurosci. 18:1998;10150-10156.
33. Jakab R.L., Goldman-Rakic P.S. 5-HT2A serotonin receptors in the primate cerebral cortex. Possible site of action of hallucinogens in pyramidal cell apical dendrites Proc Natl Acad Sci USA. 95:1998;735-740.
34. 2 antagonistic properties. J Pharmacol Exp Ther. 244:1988;685-693.
35. 2 receptor-mediated behavior, head-twitch response, in mice. Life Sci. 63:1998;2305-2311.
36. Kingston A.E., Ornstein P.L., Wright R.A., Johnson B.G., Mayne N.G., Burnett J.P., Belagaje R., Wu S., Schoepp D.D. LY341495 is a nanomolar potent and selective antagonist of group II metabotropic glutamate receptors. Neuropharmacology. 37:1998;1-12.
37. Lopez-Gimenez J.F., Mengod G., Palacios J.M., Vilaro M.T. Selective visualization of rat brain 5-HT2A receptors by autoradiography with [3H]MDL 100,907. Naunyn-Schmiedeberg's Arch Pharmacol. 356:1997;446-454.
38. Lucki I., Minugh-Purvis N. Serotonin-induced head shaking behavior in rats does not involve receptors located in the frontal cortex. Brain Res. 420:1987;403-406.
39. Lucki I., Nobler M.S., Frazer A. Differential actions of serotonin antagonists on two behavioral models of serotonin receptor activation in the rat. J Pharmacol Exp Ther. 228:1984;133-139.
40. 2A receptors on neurons in the rat piriform cortex. J Pharmacol Exp Ther. 278:1996;1373-1382.
41. 2A receptor-induced EPSCs in layer V pyramidal cells of prefrontal cortex. block by lesions of medial thalamus Soc for Neurosci Abstr. 25:1999;449.
42. Marek G.J., McDougle C.J., Price L.H., Seiden L.S. A comparison of trazodone and fluoxetine. implications for a serotonergic mechanism of antidepressant action Psychopharmacol. 109:1992;2-11.
43. 2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 292:2000;76-87.
44. 2 receptors in rat brain. Neuropsychopharmacol. 2:1989;81-87.
45. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacol. 21:1999;106S-115S.
46. i values. J Pharmacol Exp Ther. 251:1989;238-246.
47. Moghaddam B., Adams B., Verma A., Daly D. Activation of glutamatergic neurotransmission by ketamine. A novel step in the pathway from the NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex J Neurosci. 17:1997;2921-2927.
48. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonists in rats. Science. 281:1998;1349-1352.
49. Monn J.A., Valli M.J., Massey S.M., Hansen M.M., Kress T.J., Wepsiec J.P., Harkness A.R., Grutsch J.L., Wright R.A., Johnson B.G., Andis S.L., Kingston A., Tomlinson R., Lewis R., Griffey K.R., Tizzano J.P., Schoepp D.D. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740). Identification of two new potent, selective and systemically active agonists for group II metabotropic glutamate receptors J Med Chem. 42:1999;1027-1040.
50. Monn J.A., Valli M.J., Massey S.M., Wright R.A., Salhoff C.R., Johnson B.G., Howe T., Alt C.A., Rhodes G.A., Robey R.L., Griffey K.R., Tizzano J.P., Kallman M.J., Helton D.R., Schoepp D.D. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740). A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties J Med Chem. 40:1997;528-537.
51. 35S]GTPγS binding study Eur J Pharmacol. 355:1998;245-256.
52. O'Brien C.P., Woody G.E., McLellan A.T. Psychiatric disorders in opioid-dependent patients. Journal of Clinical Psychiatry. 45:1984;9-13.
53. Ohishi H., Neki A., Mizuno N. Distribution of a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat and mouse. an immunohistochemical study with a monoclonal antibody Neuroscience Res. 30:1997;65-82.
54. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the messenger RNA for a metabotropic glutamate receptor, mGluR2, in the central nervous system of the rat. Neuroscience. 53:1993;1009-1018. a.
55. Ohishi H., Shigemoto R., Nakanishi S., Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR3) in the rat brain. an in situ hybridization study J Comp Neurol. 335:1993;252-266. b.
56. Peroutka S.J., Lebovitz R.M., Snyder S.H. Two distinct central serotonin receptors with different physiological function. Science. 212:1981;827-829.
57. 2C receptors Mol Brain Res. 23:1994;163-178.
58. 1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI). Neurosci Lett. 115:1990;74-80.
59. 2A receptor mRNA levels in rat brain following irreversible inactivation with EEDQ. Mol Brain Res. 39:1996;198-206.
60. 2 binding affinity. Neuropsychopharmacology. 1:1988;101-107.
61. Schoepp D.D., Johnson B.G., Wright R.A., Salhoff C.R., Mayne N.G., Wu S., Cockerham S.L., Burnett J.P., Belagaje R., Bleakman D., Monn J.A. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors. Neuropharmacology. 36:1997;1-11.
62. Schoepp D.D., Monn J.A., Marek G.J., Aghajanian G.K., Moghaddam B. LY354740. A systemically active mGlu2/3 receptor agonist CNS Drug Reviews. 5:1999;1-12.
63. Schreiber R., Brocco M., Audinot V., Gobert A., Veiga S., Millan M.J. 1-(2,5-Dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT)2A receptors. Modulation by novel 5-HT2A/2C antagonists, D1 antagonists and t-HT1A agonists J Pharmacol Exp Ther. 273:1995;101-112.
64. 2 receptor as a site of action for LSD and phenethylamine hallucinogens. Psychopharmacol. 94:1988;213-216.
65. Tizabi Y., Russell L.T., Johnson M., Darmani N.A. Head-twitch response induced by DOI is attenuated by nicotine pretreatment. Soc Neurosci Abstr. 25:1999;60.
66. Vetulani J., Bednarczyk B., Reichenberg K., Rokosz A. Head twitches induced by LSD and quipazine. similarities and differences Neuropharmacol. 19:1980;155-158.
67. Vollenweider F.X., Vollenweider-Scherpenhuyzen M.F.I., Babler A., Vogel H., Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. 9:1998;3897-3902.
68. 2 receptors of normal human brain in vitro. Eur J Pharmacol. 132:1986;115-121.
69. Wilcox C.S., Ferguson J.M., Dale J.L., Heiser J.F. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull. 32:1996;335-342.
70. Willins D.L., Deutch A.Y., Roth B.L. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
71. Willins D.L., Meltzer H.Y. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats. J Pharmacol Exp Ther. 282:1997;699-706.
72. Wing L.L., Tapson G.S., Geyer M.A. 5-HT-2 mediation of acute behavioral effects of hallucinogens in rats. Psychopharmacol. 100:1990;417-425.
73. 2receptor subtype mRNAs in rat brain. J Comp Neurol. 351:1995;357-373.
74. 2 receptors in the wet-dog shake behaviour induced by 5-hydroxtryptophan in the rat. Neuropharmacol. 22:1983;801-804.